ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
Company profile
Ticker
OBSVF, OBSVF
Exchange
Website
CEO
Ernest Loumaye
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ObsEva USA, Inc. • ObsEva Ireland Limited • ObsEva Europe B.V. ...
OBSVF stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Apr 23
8-K
Entry into a Material Definitive Agreement
11 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
Transcripts
Latest ownership filings
SC 13D
Loumaye Ernest
17 Apr 23
4
Ernest Loumaye
11 Apr 23
4
Ernest Loumaye
2 Mar 23
4
William Michael Brown
24 Feb 23
SC 13G/A
Loumaye Ernest
14 Feb 23
3/A
Ernest Loumaye
14 Feb 23
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
6 Feb 23
3
Edward T Mathers
3 Jan 23
3
Catarina Edfjall
3 Jan 23
3
ANNE VANLENT
3 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
9.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 0 |
Closed positions | 21 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 68.42 mm |
Total shares | 9.79 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sofinnova Venture Partners VIII | 4.75 mm | $795.00 k |
Capital VII FCPR Sofinnova | 3.28 mm | $48.16 mm |
Medicxi Growth I | 1.57 mm | $3.27 mm |
Cutter & CO Brokerage | 147.70 k | $14.77 mm |
Banque Cantonale Vaudoise | 25.00 k | $3.00 k |
Laurel Wealth Advisors | 13.00 k | $1.42 mm |
Simplex Trading | 1.49 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Apr 23 | Loumaye Ernest | Common Shares | Buy | Acquire P | No | No | 0.095 | 4,000,000 | 380.00 k | 10,000,000 |
28 Feb 23 | Loumaye Ernest | Common Shares | Buy | Acquire P | No | No | 0.11 | 4,000,000 | 440.00 k | 6,000,000 |
23 Feb 23 | William Michael Brown | Employee Stock Option Common Shares | Grant | Acquire A | No | No | 0.1686 | 250,000 | 42.15 k | 250,000 |